Recommendations for measuring HIV reservoir size in cure-directed clinical trials
Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, Michel C Nussenzweig, Bonnie J Howell, Javier Martinez-Picado, Nicolas Chomont, Katharine J Bar, Xu G Yu, Mathias Lichterfeld, Jose Alcami, Daria Hazuda, Frederic Bushman, Janet D Siliciano, Michael R Betts, Adam M Spivak, Vicente Planelles, Beatrice H Hahn, Davey M Smith, Ya-Chi Ho, Maria J Buzon, Christian Gaebler, Mirko Paiardini, Qingsheng Li, Jacob D Estes, Thomas J Hope, Jay Kostman, Karam Mounzer, Marina Caskey, Lawrence Fox, Ian Frank, James L Riley, Pablo Tebas, Luis J Montaner, BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection, Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, Michel C Nussenzweig, Bonnie J Howell, Javier Martinez-Picado, Nicolas Chomont, Katharine J Bar, Xu G Yu, Mathias Lichterfeld, Jose Alcami, Daria Hazuda, Frederic Bushman, Janet D Siliciano, Michael R Betts, Adam M Spivak, Vicente Planelles, Beatrice H Hahn, Davey M Smith, Ya-Chi Ho, Maria J Buzon, Christian Gaebler, Mirko Paiardini, Qingsheng Li, Jacob D Estes, Thomas J Hope, Jay Kostman, Karam Mounzer, Marina Caskey, Lawrence Fox, Ian Frank, James L Riley, Pablo Tebas, Luis J Montaner, Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, Michel C Nussenzweig, Bonnie J Howell, Javier Martinez-Picado, Nicolas Chomont, Katharine J Bar, Xu G Yu, Mathias Lichterfeld, Jose Alcami, Daria Hazuda, Frederic Bushman, Janet D Siliciano, Michael R Betts, Adam M Spivak, Vicente Planelles, Beatrice H Hahn, Davey M Smith, Ya-Chi Ho, Maria J Buzon, Christian Gaebler, Mirko Paiardini, Qingsheng Li, Jacob D Estes, Thomas J Hope, Jay Kostman, Karam Mounzer, Marina Caskey, Lawrence Fox, Ian Frank, James L Riley, Pablo Tebas, Luis J Montaner, BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection, Mohamed Abdel-Mohsen, Douglas Richman, Robert F Siliciano, Michel C Nussenzweig, Bonnie J Howell, Javier Martinez-Picado, Nicolas Chomont, Katharine J Bar, Xu G Yu, Mathias Lichterfeld, Jose Alcami, Daria Hazuda, Frederic Bushman, Janet D Siliciano, Michael R Betts, Adam M Spivak, Vicente Planelles, Beatrice H Hahn, Davey M Smith, Ya-Chi Ho, Maria J Buzon, Christian Gaebler, Mirko Paiardini, Qingsheng Li, Jacob D Estes, Thomas J Hope, Jay Kostman, Karam Mounzer, Marina Caskey, Lawrence Fox, Ian Frank, James L Riley, Pablo Tebas, Luis J Montaner
Abstract
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
Conflict of interest statement
Competing interests:
BH, DH are employees of Merck & Co.; RFS is an inventor on a patent application on the IPDA filed by JHU and licensed to AccelevirDx (RFS holds no equity on AccelevirDx).
Figures
Source: PubMed